25 August 2020
The international iReceptor Plus consortium has gathered data of almost 200 million sequences of T and B cell receptor repertoires from COVID-19 patients. It is now offering its technology tools and infrastructure to share and analyze this unprecedented data resource with the scientific community, drug companies and researchers.
The EU- and Canadian-funded project currently offers information from seven different COVID-19 research studies carried out in the United States, Germany, the United Kingdom and China, with multiple patients through the iReceptor Gateway. This data is critical to the search for anti-COVID-19 therapeutics and vaccines. iReceptor Plus intends to add additional data sets in the coming weeks.
iReceptor Plus is dedicated to sharing and analyzing antibody and T-cell receptor (AIRR-seq) data from the immune system to accelerate vaccine discovery against pathogens such as the novel coronavirus.
“The new data can lead to discovering biomarkers, which can provide tools for diagnosis and treatment to prevent infection from COVID-19,” said Gur Yaari, associate professor at Bar-Ilan University, iReceptor Plus Project coordinator. “The COVID-19 data sets provide the infrastructure and data for the benefit of researchers in academia and industry alike.”
Print21 September 2023
September 21 is World Alzheimer's Day. NovaMedica supports this awareness raising campaign
21 September 2023
12 September 2023
AI-supported spectroscopy delivers superior pharmaceutical packaging QC
03 October 2023
Lymphoma maintenance therapy delivers promise in CTCL
03 October 2023
02 October 2023
The FAS implemented 864 new drug prices in 2022
02 October 2023